TNGXTango Therapeutics, Inc.


$ 11.34 $ -0.06 (-0.53 %)    

Wednesday, 28-Aug-2024 15:59:59 EDT
QQQ $ 468.16 $ -5.41 (-1.13 %)
DIA $ 411.36 $ -1.55 (-0.38 %)
SPY $ 558.32 $ -3.26 (-0.58 %)
TLT $ 97.88 $ -0.12 (-0.12 %)
GLD $ 231.76 $ -1.64 (-0.7 %)
$ 11.34
$ 11.33 x 140
$ 11.35 x 190
-- - --
$ 5.15 - $ 13.03
354,068
na
1.22B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-maintains-outperform-on-tango-therapeutics-raises-price-target-to-13

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target fro...

 jefferies-initiates-coverage-on-tango-therapeutics-with-buy-rating-announces-price-target-of-19

Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Pric...

 cantor-fitzgerald-reiterates-overweight-on-tango-therapeutics

Cantor Fitzgerald analyst Eric Schmidt reiterates Tango Therapeutics (NASDAQ:TNGX) with a Overweight.

 hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $13 price ...

 hc-wainwright--co-maintains-buy-on-tango-therapeutics-lowers-price-target-to-13

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price targ...

 guggenheim-maintains-buy-on-tango-therapeutics-lowers-price-target-to-14

Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $16 to...

 barclays-maintains-overweight-on-tango-therapeutics-lowers-price-target-to-13

Barclays analyst Peter Lawson maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and lowers the price target from ...

 tango-therapeutics-shuts-early-stage-cancer-study-due-to-liver-toxicity

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...

 wedbush-maintains-outperform-on-tango-therapeutics-lowers-price-target-to-11

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target fro...

 tango-therapeutics-reports-discontinuation-of-tng348-program-says-grade-34-liver-function-abnormalities-were-observed-in-patients-remaining-on-study-longer-than-eight-weeks

TNG348 was being studied in a phase 1/2 clinical trial evaluating safety, pharmacokinetics, pharmacodynamics and efficacy as a ...

 hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-17-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $17 price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION